Prevention Trials: Their Place in How We Understand the Value of Prevention Strategies

被引:18
作者
Colditz, Graham A. [1 ]
Taylor, Philip R. [2 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
来源
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 | 2010年 / 31卷
关键词
durability; adherence; bias; behavior modification; drugs; intention-to-treat; HEALTHY POSTMENOPAUSAL WOMEN; SURGICAL ADJUVANT BREAST; ESTROGEN PLUS PROGESTIN; DESIGN AFFECTS OUTCOMES; CANCER PREVENTION; PUBLIC-HEALTH; COLORECTAL ADENOMAS; ADOLESCENT DIET; BETA-CAROTENE; LUNG-CANCER;
D O I
10.1146/annurev.publhealth.121208.131051
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Several key factors bear on the interpretation of prevention trials and observational studies that inform prevention strategies. These factors include the underlying disease process and aspects of the intervention: sustainability of behavior change, the time course of the intervention within the disease process, dose and duration of exposure needed to effect risk reduction, durability of the impact of intervention, and methodological problems in implementing and interpreting randomized trials and observational studies to evaluate prevention strategies. The question asked through an intent-to-treat analysis of a randomized controlled trial (RCT) differs from that in the observational setting. Furthermore, the long duration necessary to conduct prevention trials and the resulting lack of adherence to therapy can bias results toward the null. A broader range of approaches to evaluate prevention interventions and programs with improved knowledge synthesis and translation to public health practice will speed our progress toward achieving public health and prevention of chronic diseases.
引用
收藏
页码:105 / 120
页数:16
相关论文
共 50 条
  • [41] How can we support best practice? A situational assessment of injury prevention practice in public health
    Sarah A. Richmond
    Sarah Carsley
    Rachel Prowse
    Heather Manson
    Brent Moloughney
    BMC Public Health, 20
  • [42] Prevention of Ovarian Cancer: Where are We Now and Where are We Going?
    Rodriguez, Isabel V.
    Ghezelayagh, Talayeh
    Pennington, Kathryn P.
    Norquist, Barbara M.
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1355 - 1366
  • [43] Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
    Dunn, Barbara K.
    Jegalian, Karin
    Greenwald, Peter
    CLINICAL CANCER PREVENTION, 2011, 188 : 21 - 47
  • [44] A critical analysis of obesity prevention policies and strategies
    Ximena Ramos Salas
    Mary Forhan
    Timothy Caulfield
    Arya M. Sharma
    Kim Raine
    Canadian Journal of Public Health, 2017, 108 : e598 - e608
  • [45] Dietary Interventions for Breast Cancer Prevention: Exploring the Role of Nutrition in Primary and Tertiary Prevention Strategies
    Pontillo, Martina
    Trio, Rossella
    Rocco, Nicola
    Cinquerrui, Ada
    Di Lorenzo, Mariana
    Catanuto, Giuseppe
    Magnoni, Francesca
    Calenda, Fabrizia
    Castiello, Carlo Luigi Junior
    Ingenito, Mafalda
    Margherita, Alessia Luciana
    Velotti, Nunzio
    Musella, Mario
    HEALTHCARE, 2025, 13 (04)
  • [46] Clinical trials of vitamin and mineral supplements for cancer prevention'
    Greenwald, Peter
    Anderson, Darrell
    Nelson, Stefanie A.
    Taylor, Philip R.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (01) : 314S - 317S
  • [47] How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
    Crew, Katherine D.
    Albain, Kathy S.
    Hershman, Dawn L.
    Unger, Joseph M.
    Lo, Shelly S.
    NPJ BREAST CANCER, 2017, 3
  • [48] Quality of randomized controlled trials in eating disorder prevention
    Watson, Hunna J.
    Goodman, Erica L.
    McLagan, Nicole B.
    Joyce, Tara
    French, Elizabeth
    Willan, Vivienne
    Egan, Sarah J.
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2017, 50 (05) : 459 - 470
  • [49] Cancer prevention programmes in Mexico: are we doing enough?
    Padilla-Raygoza, Nicolas
    Monroy-Torres, Rebeca
    Sandoval-Salazar, Cuauhtemoc
    Elvia Vera-Becerra, Luz
    Esther Patino-Lopez, Maria
    de Lourdes Garcia-Campos, Maria
    Beltran Campos, Vicente
    Ortega Jimenez, Mayra del Carmen
    del Carmen Delgado-Sandoval, Silvia
    Sofia Ramirez-Gomez, Xochitl
    Neli Jimenez-Garcia, Sandra
    Lissette Lopez-Lemus, Hilda
    ECANCERMEDICALSCIENCE, 2020, 14
  • [50] Phytochemicals in Cancer Treatment and Cancer Prevention-Review on Epidemiological Data and Clinical Trials
    Rudzinska, Anna
    Juchaniuk, Pola
    Oberda, Jakub
    Wisniewska, Jolanta
    Wojdan, Witold
    Szklener, Katarzyna
    Mandziuk, Slawomir
    NUTRIENTS, 2023, 15 (08)